Abstract
Vaccinations have been given to people for at least 100 years of which 80 years formulated in adjuvants. Currently, aluminium- containing formulas and the oil-based substance called MF59 are the two adjuvants licensed for clinical use. Despite the massive use of aluminium adjuvant, its mechanism of action has been only recently addressed. In this review, we will discuss both the cellular and molecular mode of action of aluminium-containing adjuvants.
Keywords: Adjuvant, aluminium hydroxide, dendritic cell, NLRP3, Syk, uric acid and dsDNA
Related Journals
Current Drug Safety
Current Medicinal Chemistry
Current Neuropharmacology
Current Pharmaceutical Analysis
Current Topics in Medicinal Chemistry
Current Vascular Pharmacology
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
CNS & Neurological Disorders - Drug Targets
Related Books
New Findings from Natural Substances
Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research – Anti Allergy Agents
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Frontiers in Inflammation
16